Analysts expect that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report ($0.29) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.32). Inovio Pharmaceuticals posted earnings per share of ($0.36) during the same quarter last year, which indicates a positive year over year growth rate of 19.4%. The company is scheduled to issue its next earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.01) to ($0.95). For the next financial year, analysts anticipate that the business will report earnings of ($1.07) per share, with EPS estimates ranging from ($1.23) to ($0.93). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). Inovio Pharmaceuticals had a negative net margin of 318.11% and a negative return on equity of 93.39%. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.69 million. During the same period in the previous year, the firm earned ($0.23) earnings per share.
INO has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 25th. BidaskClub downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 7th. Zacks Investment Research downgraded Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 14th. Maxim Group reissued a “buy” rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald initiated coverage on Inovio Pharmaceuticals in a research note on Monday, March 25th. They set an “overweight” rating and a $3.62 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $7.57.
A number of institutional investors and hedge funds have recently modified their holdings of INO. D. E. Shaw & Co. Inc. increased its stake in Inovio Pharmaceuticals by 125.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,073,086 shares of the biopharmaceutical company’s stock worth $4,292,000 after acquiring an additional 596,684 shares during the last quarter. Defender Capital LLC. bought a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $2,324,000. Dimensional Fund Advisors LP increased its stake in Inovio Pharmaceuticals by 446.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 520,426 shares of the biopharmaceutical company’s stock worth $2,894,000 after acquiring an additional 425,188 shares during the last quarter. FMR LLC bought a new stake in Inovio Pharmaceuticals in the 3rd quarter worth approximately $2,221,000. Finally, BlackRock Inc. increased its stake in Inovio Pharmaceuticals by 4.2% in the 4th quarter. BlackRock Inc. now owns 7,251,925 shares of the biopharmaceutical company’s stock worth $29,008,000 after acquiring an additional 292,584 shares during the last quarter. 36.43% of the stock is currently owned by institutional investors.
Shares of INO stock traded up $0.06 during trading hours on Tuesday, reaching $3.86. 882,175 shares of the company traded hands, compared to its average volume of 1,291,290. The stock has a market cap of $370.99 million, a P/E ratio of -3.68 and a beta of 1.72. Inovio Pharmaceuticals has a 12-month low of $3.02 and a 12-month high of $6.30.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.